Implantable Polymeric Device for Sustained Release of Buprenorphine

Abstract

The present invention provides compositions, methods, and kits for treatment of opiate addiction and pain. The invention provides a biocompatible nonerodible polymeric device which releases buprenorphine continuously with generally linear release kinetics for extended periods of time. Buprenorphine is released through pores that open to the surface of the polymeric matrix in which it is encapsulated. The device may be administered subcutaneously to an individual in need of continuous treatment with buprenorphine.

1 - 36 . (canceled) 
     
     
         37 . A method of providing buprenorphine to a human, the method comprising subcutaneously implanting buprenorphine into the human. 
     
     
         38 . The method of  claim 37 , wherein the buprenorphine is provided as an implantable device, wherein the implantable device comprises a carrier. 
     
     
         39 . The method of  claim 38 , wherein the carrier comprises a polymer. 
     
     
         40 . The method of  claim 39 , wherein the polymer is non-erodible. 
     
     
         41 . The method of  claim 39 , wherein the polymer is ethylene vinyl acetate. 
     
     
         42 . The method of  claim 37 , wherein the human receives a non-zero plasma concentration of buprenorphine for at least 3 months. 
     
     
         43 . The method of  claim 37 , wherein the buprenorphine is a pharmaceutically-acceptable salt. 
     
     
         44 . The method of  claim 37 , wherein the buprenorphine is buprenorphine hydrochloride. 
     
     
         45 . The method of  claim 37 , wherein the human receives a plasma level of buprenorphine from about 0.1 ng/ml to about 70 ng/ml. 
     
     
         46 . The method of  claim 37 , wherein the human receives a plasma level of buprenorphine from about 1.0 ng/ml to about 10 ng/ml. 
     
     
         47 . The method of  claim 37 , wherein the human receives a plasma level of buprenorphine from about 0.1 ng/ml to about 0.5 ng/ml. 
     
     
         48 . The method of  claim 37 , wherein the human receives a plasma level of buprenorphine of about 0.5 ng/ml.